Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Steroid supplements destroyed

This article was originally published in The Tan Sheet

Executive Summary

Under a consent decree, $1.3 million in LG Sciences' bodybuilding supplements are condemned and forfeited for destruction, FDA reports May 11. LG products including Methyl 1-D, Methyl 1-D XL and Formadrol Extreme XL were found to contain unapproved food additives or new dietary ingredients. The consent decree in the U.S. District Court for the Eastern District of Michigan, Southern Division, follows FDA's order to seize the products from Brighton, Mich.-based LG in April 2008 (1"The Tan Sheet" April 7, 2008, In Brief)

You may also be interested in...

Supplements seized

Federal investigators seized more than $1 million in strength-training supplements from LG Sciences in Brighton, Mich., on April 2 after the firm failed to respond to FDA's warnings about the use of adulterated ingredients in the products, the agency says. FDA asked the U.S. Marshalls Service and the U.S. Attorney's Office in the Eastern District of Michigan to seize the Methyl 1-D, Methyl 1-D XL and Formadrol Extreme XL products from LG Sciences, according to an April 4 release. The firm's products, which were cited in a March 2006 warning letter from the agency, allegedly contain one or more unapproved food additives or new dietary ingredients that lack adequate evidence to show they are safe, FDA says. LG Sciences legal representative, Ronald Berry, said the products' ingredients are "perfectly" compliant with the Dietary Supplement Health and Education Act. Berry added the products' seizure "makes no determination of liability or the correction of [FDA's] allegations"....

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts